Clinical Chemistry, Emerging Omics Technologies
Measuring the exposome or totality exposures over individuals’ lifetime, offers new insight into exposure-response relationships (biological epidemiology) by determining and differentiating the causal pathways (exposure biology) and reactive pathways (systems biology) in chronic human disease. Through the application of discovery-based omics and targeted methodologies to measure the exposome, exposomics will identify new biomarkers of disease, guide methods to mitigate exposures, and ultimately lead to more personalized medical interventions. Volatile organic solvent exposure, such as benzene or toluene, is an example of an exposure biomarker (the causal disease pathway) that leads to primary and secondary disease traits as evidenced by perturbations in the urinary organic acid profile (the reactive disease pathway). This application note presents a top-down, targeted approach of measuring the urinary organic acid exposome using GC/MS and post-acquisition mass spectral deconvolution with targeting library searching.
Publication number: 5991-3541EN.pdf
Publication Date: November 22, 2013